Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flow from investing activities | ||
| Purchase of short-term marketable debt securities | (59,068) | (88,548) |
| Proceeds from maturities of short-term marketable debt securities | 59,166 | 144,829 |
| Purchase of property and equipment | — | (35) |
| Net cash flow provided by investing activities | 98 | 56,246 |
| Cash flow from financing activities | ||
| Proceeds from long-term debt, net of issuance costs | 24,467 | 73,022 |
| Issuance of Class A Ordinary Shares, net of transaction costs | 6,007 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's capex?
- MoonLake Immunotherapeutics (MLTX) reported capex of $0 in Q1 2026.
- How has MoonLake Immunotherapeutics's capex changed year-over-year?
- MoonLake Immunotherapeutics's capex decreased by 100.0% year-over-year, from $35K to $0.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about MoonLake Immunotherapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude